Subscribe to Newsletter
Business & Profession Basic & Translational Research, Cornea / Ocular Surface, Glaucoma, Imaging & Diagnostics, Retina, Refractive, Professional Development, Business and Innovation, Health Economics and Policy

Also in the News…

LittleT889, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons

iCare MAIA microperimeter. iCare, an ophthalmic diagnostics subsidiary of the Revenio Group, has launched a new version of its MAIA microperimeter. Retaining all the key features of the original, the latest model boasts an intuitive user interface on a 15’’ multi-touch display and a 60° TrueColor field of view. Notably, clinicians are able to import data from the previous model to ensure full continuity with a patient’s clinical history. Link

Corneal implant candidates. Pantheon Vision announced the completion of a third “productive and successful meeting” with the FDA review team. “We anticipate another check in with the FDA in the spring, when we reach another milestone in the development of our advanced bioengineered solution for treating corneal blindness,” said Pantheon CEO John Sheets. Link

Retinal degeneration study. Researchers from Istituto Italiano di Tecnologia, Milan, Italy, have developed a membrane-targeted photoswitch capable of reinstating natural ON and OFF light responses in the degenerate retina. In mouse models, Ziapin2 successfully reactivated retinal ganglion cells, improving light-driven behavior and optomotor reflexes by modulating neuronal capacitance without genetic modification or implants. The team believes this non-invasive therapy could pave the way for future treatments to restore functional vision in patients with retinal degeneration. Link

Optometrists’ management of nAMD. A recent Wales-based study by The College of Optometrists looks at the value of having optometrists play a greater role in managing neovascular age-related macular degeneration (AMD) and glaucoma in UK primary care. The study revealed significant reductions in patient wait times, which would allow ophthalmologists to focus on complex cases while maintaining cost-effectiveness and efficiency. Despite pointing out potential administrative and IT support challenges, the study supports expanding optometry-led eye care services to improve patient access and alleviate hospital burdens. Link

The anti-VEGF landscape. An IOVS study provides an overview of anti-VEGF therapies as well as the real-world challenges that are encountered by physicians in maintaining therapeutic outcomes. In addition to evaluating currently available anti-VEGF therapies, the Washington University School of Medicine researchers also investigate VEGF inhibitors that are still in clinical development. Link

NEWS

The Ophthalmologist Presents:

The Ophthalmologist Weekly Newsletter

Enjoying yourself? There's plenty more where that came from! Our weekly newsletter from The Ophthalmologist brings you the most popular stories as they unfold, chosen by our fantastic Editorial team!

Register for our weekly newsletter

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at info@theophthalmologist.com.
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Alun Evans
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: